Welcome to our dedicated page for Wiley John & Sons news (Ticker: WLY), a resource for investors and traders seeking the latest updates and insights on Wiley John & Sons stock.
John Wiley & Sons, Inc. reports developments across its research publishing, research intelligence, and learning businesses. Company news commonly covers quarterly results, Research and Learning performance, AI and data services initiatives, scientific and medical content licensing, open access and journal portfolio expansion, and technology partnerships supporting customer platforms.
Wiley updates also include book publishing announcements, quarterly dividends, share repurchase activity, and leadership changes tied to its Research organization. Its disclosures frequently reference authoritative content, peer-reviewed journals, courseware, assessments, and platforms serving researchers, students, instructors, professionals, institutions, corporations, and R&D teams.
Wiley (NYSE:WLY) will release its fourth quarter and fiscal 2026 earnings before market open on Tuesday, June 16, 2026. Management will host a conference call at 10:00 a.m. ET to discuss the results, with access via webcast and dedicated phone lines.
Wiley (NYSE: WLY) agreed to acquire Emerald Publishing for £337 million (USD 452 million) in an all-cash deal valued at ~7x Adjusted EBITDA including cost synergies. The acquisition expands Wiley’s journal portfolio to ~2,500 titles, strengthens leadership in social sciences, and deepens proprietary content for AI.
Emerald is expected to generate over USD 85 million revenue in 2026 with mid-single-digit growth, 92% recurring subscription revenue, and 85% generated outside North America. Wiley targets ~USD 30 million annual run-rate cost synergies by year three, and expects the deal to be accretive to Adjusted EPS in year one.
Wiley (NYSE:WLY) released the Wiley Registry of Mass Spectral Data 2026, expanding coverage to over 915,500 reference spectra. The new edition adds more than 42,000 GC-MS spectra representing 34,100 compounds, supporting AI-assisted and traditional laboratory workflows across pharmaceuticals, forensics, environment, and materials science.
Wiley (NYSE: WLY) appointed Jessica Kowalski as Executive Vice President and General Manager, Research, effective May 11, 2026. Kowalski joins from Microsoft with two decades in publishing, data and AI, succeeding Jay Flynn, who is leaving the company.
The move aims to accelerate Wiley's AI-enabled research publishing, translate content into new products and business models, and deepen partnerships after recent AI leadership hires.
Wiley (NYSE:WLY) will publish chef Geoffrey Zakarian's new book Original Food: Recapturing the Joy of Eating on October 27, 2026. The book mixes culinary storytelling, more than 20 new recipes, and a research-based approach to whole, minimally processed ingredients for healthier everyday cooking.
Zakarian presents meal planning, chef-tested techniques, and guidance for families seeking practical, flavorful alternatives to ultra-processed foods. Preorder links and social channels are provided.
Wiley (NYSE: WLY) declared a quarterly cash dividend of $0.355 per share, payable April 23, 2026, to holders of record April 7, 2026, equal to an annualized $1.42 per share (up from $1.41 in Fiscal 2025).
The company also increased its Fiscal 2026 share repurchase allocation to $100 million (up from $60 million in Fiscal 2025 and $45 million in Fiscal 2024). On March 5, 2026, Wiley reported Q3 Fiscal 2026 results citing momentum in Research and AI, margin expansion, and cash flow growth.
Wiley (NYSE: WLY) reported Q3 FY2026 results: GAAP revenue of $410M (+1%), operating income $63M (+21%), GAAP EPS $0.56 vs loss prior year, and adjusted EPS $0.97 (+19% at constant currency).
Adjusted operating income rose 22% with a 280 basis-point margin expansion; adjusted EBITDA margin reached 25.7%. Free cash flow improved to $56M YTD and the company is on track for ~$200M FCF in FY2026. AI and Research momentum continued with $7M AI revenue in the quarter and multi-year partnerships announced. Share repurchases increased, targeting $100M for the full year.
Wiley (NYSE: WLY) and OpenEvidence announced a strategic partnership on March 3, 2026 to license Wiley’s scientific and medical content into OpenEvidence’s AI clinical platform.
The agreement covers the Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, and over 400 Wiley journals and books, broadening point-of-care, source-cited evidence for clinicians.
Wiley (NYSE: WLY) will release third quarter 2026 results before market open on March 5, 2026 and hold a conference call at 10:00 AM ET the same day. Investors can access a live webcast at the company Investor Relations site or dial in via provided US, Canada, and international numbers with participant code 2521217#.
The company said the call will discuss the Q3 2026 results and related business updates.
Wiley (NYSE: WLY) will expand its Advanced journals portfolio into life, health and social sciences, planning to launch eight new journals by end of 2026 and additional titles thereafter. The move extends the portfolio beyond materials science and adds titles such as Advanced Oncology, opening for submissions next month.
The portfolio uses a streamlined editorial model where authors submit once and editors place papers across journals to reduce resubmission and formatting cycles, and Wiley is co-sponsoring the MD Anderson Cancer and Neuroscience Symposium Feb 19–20.